Welcome to our dedicated page for Pure Bioscience news (Ticker: PURE), a resource for investors and traders seeking the latest updates and insights on Pure Bioscience stock.
PURE Bioscience, Inc. (OTCQB: PURE) is a manufacturing company focused on antimicrobial technology for food safety and the food and beverage industry. Its news flow centers on the development, commercialization, and distribution of products built on its patented, stabilized ionic silver platform, particularly silver dihydrogen citrate (SDC), a broad-spectrum, non-toxic antimicrobial agent.
News updates for PURE often include financial results for fiscal quarters and years, where the company reports net product sales, royalty revenue, gross profit, operating expenses, and net loss. These releases also discuss trends in sales across direct customers and distribution networks, as well as efforts to manage operating costs and secure financing through convertible notes payable to related parties.
Another key category of PURE news involves product and technology developments. The company has announced an SDC-based membrane treatment solution for dairy and beverage producers, using its PURE Hard Surface product to address membrane fouling and sanitization in ultrafiltration and reverse osmosis systems. Updates describe performance attributes such as microbial reduction, restoration of throughput, and non-oxidizing behavior, along with pilot work at a California State University Dairy Pilot Processing Center.
PURE also issues news about distribution agreements and partnerships, such as multi-year arrangements with Hydrite Chemical Company and Bonsai, which expand access to its EPA-registered disinfectants, cleaners, and sanitizers across food processing, dairy, transportation, and online channels. Additional releases cover corporate developments, including leadership changes, rebranding initiatives, and proxy-related matters disclosed through SEC filings. Investors and industry observers can use the PURE news feed to follow the company’s operational performance, market expansion efforts, and strategic direction in antimicrobial and sanitation technologies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
PURE Bioscience, Inc. (OTCQB: PURE) reported its Q2 and six-month results ended January 31, 2023. Net product sales decreased to $396,000 in Q2 from $415,000 in 2022, with a net loss of $1,060,000 compared to $702,000 in the same quarter last year. For the six months, sales totaled $863,000, down from $912,000, with losses rising to $2,053,000 versus $1,498,000 year-over-year. The company appointed Robert Bartlett as the new CEO on March 15, 2023, aiming to enhance revenue and redirect sales strategies.
PURE Bioscience reported its fiscal first quarter results for the period ending October 31, 2022, with net product sales of $467,000, down from $497,000 in the previous year. The company faced a net loss of $993,000, compared to $796,000 year-over-year. Despite these challenges, substantial adoption of the SDC-based antimicrobial in potato, snack food, and bakery sectors is noted, alongside growth in the dairy industry. New regional managers have been hired to enhance sales efforts across multiple industries. CEO Tom Y. Lee highlighted positive momentum and industry acceptance.
Hydrite has secured a multi-year exclusive distribution agreement with PURE Bioscience, Inc. for its PURE® Hard Surface disinfectant in the dairy and plant-based protein markets. This SDC-based product is designed to effectively eliminate foodborne pathogens. With Hydrite's established presence in dairy processing, the partnership aims to enhance food safety and sanitation solutions. The agreement positions PURE® Hard Surface as an essential tool for dairy and plant-based protein facilities, allowing for improved sanitation practices.
PURE Bioscience reported a net product sales decrease to $1.81 million for the fiscal year ending July 31, 2022, down from $3.70 million in 2021. The net loss rose to $3.5 million, compared to $2.3 million the previous year. The company's reliance on distributors has shifted, with a newly formed in-house sales team aiming to capitalize on the janitorial and sanitation markets. Leadership expressed optimism for revenue growth in the upcoming quarters as they broaden their market reach.
PURE Bioscience, Inc. (OTCQB: PURE) reported Q3 financial results for the period ended April 30, 2022. Net product sales fell 11% to $497,000 from $556,000 in the previous year, attributed to reduced distributor sales. Royalties increased to $27,000 from $5,000. The company reported a net loss of $760,000, slightly improved from $811,000 a year earlier. For the nine-month period, net sales decreased 50% to $1.4 million and net loss rose to $2.26 million. New distribution agreements and management hires aim to enhance growth in the food safety and sanitation sectors.